Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases

• New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress
• Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax' COVID-19 vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will provide a first look at data from its COVID-19 influenza combination vaccine and seasonal influenza vaccine trials, at the World Vaccine Congress (WVC) in Washington, DC, April 18 - 21, 2022. In addition, the latest data on its protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be presented at both WVC and the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in in Lisbon, Portugal, April 23 - 26, 2022. Data from eight abstracts and presentations, including four oral presentations, will be presented across the two congresses.

Gregory M. Glenn, M.D., President, Research and Development, Novavax, said: "Our presence at these two leading industry conferences shows our ongoing commitment to addressing COVID-19, and the advances we have made towards a next-generation influenza vaccine. We look forward to sharing these updates that further demonstrate the potential for our platform."

Key Novavax presentations during WVC:

Glenn, GHow long will our immunityagainst COVID-19 last forand will our vaccinescontinue to work againstVoCs?PanelApril 19, 20228:45 - 9:45 ETKim, DMonitoring COVID-19 VaccineSafety under Emergency UseAuthorization: Challenges andLessons?PanelApril 20, 202212:10 - 1:10 ETGlenn, GClinical Update on Novavax'sRecombinant Nanoparticle ProteinSubunit COVID-19 Vaccine as aBoosterOralSession COVID & Beyond - M4April 20, 202212:40 - 12:00 ETShinde, VUpdate on Novavax' NanoFlu*vaccine and COVID-19-InfluenzaCombination Vaccine developmentOralSession Influenza and Respiratory - M4April 20, 202212:40 - 1:10 ET

*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.

Key Novavax presentations during ECCMID:

Toback, SOngoing safety and efficacyof the NVX-CoV2373 COVID-19vaccine in the United KingdomAbstract #04525OralSession Late breaking updates on COVID vaccinationApril 25, 202216:15 - 17:15 CETShinde, VLong-term durability ofantigen-specific polyfunctionalCD4+ T cell responses againstvaccine-homologous andantigenically drifted viruses:results of a phase III trialof a recombinant quadrivalenthemagglutinin saponin-adjuvantednanoparticle influenzaAbstract #1197OralSession Viral respiratory infections: Influenza and RSVApril 26, 202211:00 - 12:00 CET??ez, GSafety, efficacy and effectivenessof a SARS-CoV-2 adjuvantedrecombinant spike proteinvaccine (NVX-CoV2373)in a phase III trial inadolescents (PREVENT-19)Abstract #04455PosterSession 12g. Vaccine development, trials, efficacy, policyApril 25, 202212:00 - 13:00 CET??ez, GMolecular epidemiology of SARS-CoV-2strains identified during a phase III,efficacy and safety trial ofNVX-CoV2373 vaccine(PREVENT-19) in theUnited States and MexicoAbstract #00284PosterSession 12l. Virus evolution, variants, and impactApril 25, 202212:00 - 13:00 CETBeyhaghi, HReported pregnancies andassociated outcomes acrossthe NVX-CoV2373 COVID-19vaccine clinical developmentprogrammeAbstract #01705PosterSession 12g. Vaccine development, trials, efficacy, policyApril 25, 202212:00 - 13:00 CETMarchese, ACOVID-19 vaccine receptivityand preferences among"vaccine hesitants"Abstract #04362PosterSession 12g. Vaccine development, trials, efficacy, policyApril 25, 202212:00 - 13:00 CET

For more information or to register, visit the World Vaccine Congress Washington 2022 and the 32nd European Congress of Clinical Microbiology & Infectious Diseases websites.

About Novavax Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and its quadrivalent influenza investigational vaccine candidate, previously referred to as NanoFlu. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M(TM) adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on LinkedIn,.

Contacts: InvestorsErika Schultz | 240-268-2022 [email protected]

MediaAli Chartan | 240-720-7804 Laura Keenan Lindsey | 202-709-7521 [email protected]

Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg